Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 11  |  Issue : 5  |  Page : 125-127

Herceptin as a single agent in the treatment of patients with metastatic breast cancer


1 Department of Breast Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province 230032; Department of Oncology Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province 233000, China
2 Department of Oncology Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province 233000, China
3 Department of Breast Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province 230032, China

Correspondence Address:
Dr. Benzhong Wang
No. 218, Jixi Road, Hefei City, Anhui Province
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.163868

Rights and Permissions

Objective: The aim of this retrospectively study was to assess the clinical efficacy and toxicity of Herceptin as a single agent in the treatment of patients with metastatic breast cancer (MBC). Methods: We retrospectively included and analyzed 31 metastasis breast cancer patients in our patient database. All of the included 31 patients were pathology confirmed of breast carcinoma with remote metastases and treated with Herceptin as a single agent. The clinical efficacy and drug-related toxicity were analyzed. Results: No complete response patients were observed for 31 cases. And 8 (26%) reached partial response 16 (52%) with stable disease. The objective response rate of the 31 patients was 23%. We further divided the 31 cases into three subgroups according to the treatment modality. The objective response rate was 36%, 14%, and 17% for the first-line, second-line, and third-line treatment modality, respectively. The objective response rate was not statistical different among the three subgroups (P > 0.05). The main drug-related adverse event were asthenia, chills, diarrhea, nausea, hypotension and dizziness with their incidence of 68%, 26%, 13%, 10%, 10%, and 6%, respectively, for each patients. Conclusion: Herceptin as a single agent was effective and safe in the treatment of patients with MBC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1737    
    Printed37    
    Emailed0    
    PDF Downloaded124    
    Comments [Add]    

Recommend this journal